Wide Ranks

MCRB

Seres Therapeutics, Inc.

0.9150

Top Statistics
Market Cap 156 M Forward PE -2.24 Revenue Growth 0.00 %
Current Ratio 1.12 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -20.17 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.12 Enterprise / Revenue 1.19 Price To Sales Trailing12 Months 1.24
Profitability
Profit Margins -20.17 % Operating Margins -33.56 %
Balance Sheet
Total Cash 66 M Total Cash Per Share 0.4950 Total Debt 93 M
Total Debt To Equity 391.37 Current Ratio 1.12 Book Value Per Share 0.1770
All Measures
Short Ratio 751.00 % Message Board Id finmb_222388947 Shares Short Prior Month 18 M
Return On Equity -15.56 City Cambridge Uuid 142fe857-307b-3629-9b7d-860e8fe50185
Previous Close 0.8770 First Trade Date Epoch Utc 1 B Book Value 0.1770
Total Debt 93 M Volume 1 M Price To Book 5.17
Fifty Two Week Low 0.5400 Total Cash Per Share 0.4950 Total Revenue 126 M
Shares Short Previous Month Date 1 B Target Median Price 1.25 Max Age 86400
Recommendation Mean 2.14 Sand P52 Week Change 0.3133 Operating Margins -33.56 %
Target Mean Price 3.87 Net Income To Common -68445000 Short Percent Of Float 0.1273
Implied Shares Outstanding 170 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 4 M Average Volume10days 4 M Total Cash 66 M
Next Fiscal Year End 1 B Revenue Per Share 0.8710 Held Percent Insiders 0.1319
Ebitda Margins -28.89 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.8770 Target Low Price 1.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.8106 Open 0.8770
Dividend Yield 0.00 % State MA Return On Assets -0.0970
Time Zone Short Name EST Trailing Eps -0.4000 Day Low 0.8585
Address1 101 Cambridgepark Drive Shares Outstanding 170 M Price Hint 4
Target High Price 10.00 Website https://www.serestherapeutics.com 52 Week Change -0.1202
Average Volume 4 M Forward Eps -0.5500 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 103.10 % Is_sp_500 False
Regular Market Day High 0.9230 Profit Margins -20.17 % Debt To Equity 391.37
Fifty Two Week High 2.05 Day High 0.9230 Shares Short 16 M
Regular Market Open 0.8770 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 1.19 Revenue Growth 0.00 % Shares Percent Shares Out 0.0951
Currency USD Time Zone Full Name America/New_York Market Cap 156 M
Is_nasdaq_100 False Zip 02140 Quote Type EQUITY
Industry Biotechnology Long Name Seres Therapeutics, Inc. Regular Market Day Low 0.8585
Held Percent Institutions 0.3718 Current Price 0.9150 Enterprise To Ebitda -4.12
Financial Currency USD Current Ratio 1.12 Gross Margins 18.41 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 98 M Two Hundred Day Average 0.8967 Enterprise Value 150 M
Price To Sales Trailing12 Months 1.24 Forward PE -2.24 Regular Market Volume 1 M
Ebitda -36498000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome.

It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection.

Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation.

In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis.

Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.

A.

(Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease.

The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015.

Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.